MediJet printer designed for anatomical models, surgical guides and medical tooling using sterilizable and biocompatible materials
EDEN PRAIRIE, Minn. & REHOVOT, Israel — (BUSINESS WIRE) — Stratasys Ltd. (NASDAQ: SSYS) today introduced a medical 3D printer that sets a new standard for healthcare providers and medical device companies by combining multiple applications in one system. With multiple materials and multi-color capabilities, the Stratasys J5 MediJet™ 3D printer enables users to create highly detailed 3D anatomical models and drilling and cutting guides with approved third-party 510k-cleared segmentation software. Guides and models are certified as sterilizable and biocompatible, and the printer is economical and compact enough for small lab spaces.
The J5 MediJet 3D printer is the newest addition to the Stratasys J5 Series™ of printers, along with the J5 DentaJet™ and J55™. In operation, it features a patented rotating build platform with a fixed print head. This is designed to maximize reliability and simplify maintenance. The system also delivers more output from a small footprint. Compared to other 3D printers, the MediJet 3D printer is up to 30 percent faster, along with a simple workflow that includes automatic build tray arrangement, corrections and support for the latest 3MF file format for simplifying connectivity to third-party segmentation and design software.
The new printer supports DraftWhite™ material for affordable single-material applications, along with a full array of new flexible, rigid color, and transparent materials. The multi-materials capabilities support a broad range of medical modeling applications in one office-friendly platform, which reduces outsourcing costs or the need for multiple printers.
“For small to midsized hospitals, we’re enabling access to models and guides with a medical-specific 3D printer that is office-friendly and affordable, while ensuring sterilization is easy so you can bring models right into the operating room with you,” said Stratasys’ Healthcare Vice President Osnat Philipp. “We also believe the J5 MediJet printer can help medical device companies bring new innovations to market faster by providing models for benchmark testing of medical devices and for product demonstrations with models showing the actual pathologies the devices are meant to treat.”
All on a certified system
The J5 MediJet printer is certified with leading 510K-cleared DICOM segmentation software packages for clinical diagnostic use. Additionally, it can print biocompatible materials that are certified for limited contact to tissue and bone, and permanent contact to intact skin (ISO 10993) and for breathing gas pathways in healthcare applications (ISO 18562). MediJet models can also be sterilized using Steam, Gamma and EtO methods specific to the print material.
The J5 MediJet material and hardware manufacturing sites have received ISO 13485 certification for the design and manufacture of medical devices.
The printer and materials are available now. Learn more about the clinical and economic value of medical 3D printing on the Stratasys website.
About Stratasys
Stratasys is leading the global shift to additive manufacturing with innovative 3D printing solutions for industries such as aerospace, automotive, consumer products and healthcare. Through smart and connected 3D printers, polymer materials, a software ecosystem, and parts on demand, Stratasys solutions deliver competitive advantages at every stage in the product value chain. The world’s leading organizations turn to Stratasys to transform product design, bring agility to manufacturing and supply chains, and improve patient care.
To learn more about Stratasys visit www.stratasys.com, the Stratasys blog, Twitter, LinkedIn, or Facebook. Stratasys reserves the right to utilize any of the foregoing social media platforms, including the company’s websites, to share material, non-public information pursuant to the SEC’s Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.
Stratasys, PolyJet, J5, J5 Series, DraftWhite, and MediJet are trademarks or registered trademarks of Stratasys Ltd. and/or its affiliates. All other trademarks are the property of their respective owners, and Stratasys assumes no responsibility with regard to the selection, performance, or use of these non-Stratasys products.
Note Regarding Forward-Looking Statement
The statements in this press release relating to Stratasys’ beliefs regarding the benefits consumers will experience from using the J5 MediJet are forward-looking statements reflecting management’s current expectations and beliefs. These forward-looking statements are based on current information that is, by its nature, subject to rapid and even abrupt change. Due to risks and uncertainties associated with Stratasys’ business, actual results could differ materially from those projected or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the degree of our success at introducing new or improved products and solutions that gain market share; the degree of growth of the 3D printing market generally; the duration of the global COVID-19 pandemic, which, if extensive, may continue to impact, in a material adverse manner, our operations, financial position and cash flows, and those of our customers and suppliers; the impact of potential shifts in the prices or margins of the products that we sell or services that we provide, including due to a shift towards lower-margin products or services; the impact of competition and new technologies; potential further charges against earnings that we could be required to take due to impairment of additional goodwill or other intangible assets; to the extent of our success at successfully consummating acquisitions or investments in new businesses, technologies, products or services; potential changes in our management and board of directors; global market, political and economic conditions, and in the countries in which we operate in particular (including risks related to the impact of coronavirus on our operations, supply chain, liquidity, cash flow and customer orders; costs and potential liability relating to litigation and regulatory proceedings; risks related to infringement of our intellectual property rights by others or infringement of others’ intellectual property rights by us; the extent of our success at maintaining our liquidity and financing our operations and capital needs; the impact of tax regulations on our results of operations and financial condition; and other risk factors set forth under the caption “Risk Factors” in Stratasys’ most recent Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 1st, 2021. Readers are urged to carefully review and consider the various disclosures made throughout our 2020 Annual Report and our other reports filed with or furnished to the SEC, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. Any guidance provided, and other forward-looking statements made, in this press release are made as of the date hereof, and Stratasys undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Source: Stratasys Ltd.
